The equivalent cytotoxicity found between all three pancreatic cancer lines using a control ADC targeting EpCAM (Figure 4B) demonstrates that the differences observed among the cell lines with the anti-SAS1B ADC are due to target density differences rather than inherent differences in how each cell line processes and responds to an ADC. Here, ASTL is linked to pancreatic neoplasm.